Diabetes, Vol 49, Issue 12 2063-2069, Copyright © 2000 by American Diabetes Association

ARTICLES

Mechanism by which metformin reduces glucose production in type 2 diabetes

RS Hundal, M Krssak, S Dufour, D Laurent, V Lebon, V Chandramouli, SE Inzucchi, WC Schumann, KF Petersen, BR Landau and GI Shulman
Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510, USA.

To examine the mechanism by which metformin lowers endogenous glucose production in type 2 diabetic patients, we studied seven type 2 diabetic subjects, with fasting hyperglycemia (15.5 +/- 1.3 mmol/l), before and after 3 months of metformin treatment. Seven healthy subjects, matched for sex, age, and BMI, served as control subjects. Rates of net hepatic glycogenolysis, estimated by 13C nuclear magnetic resonance spectroscopy, were combined with estimates of contributions to glucose production of gluconeogenesis and glycogenolysis, measured by labeling of blood glucose by 2H from ingested 2H2O. Glucose production was measured using [6,6-2H2]glucose. The rate of glucose production was twice as high in the diabetic subjects as in control subjects (0.70 +/- 0.05 vs. 0.36 +/- 0.03 mmol x m(-2) min(-1), P < 0.0001). Metformin reduced that rate by 24% (to 0.53 +/- 0.03 mmol x m(-2) x min(-1), P = 0.0009) and fasting plasma glucose concentration by 30% (to 10.8 +/- 0.9 mmol/l, P = 0.0002). The rate of gluconeogenesis was three times higher in the diabetic subjects than in the control subjects (0.59 +/- 0.03 vs. 0.18 +/- 0.03 mmol x m(-2) min(-1) and metformin reduced that rate by 36% (to 0.38 +/- 0.03 mmol x m(-2) x min(-1), P = 0.01). By the 2H2O method, there was a twofold increase in rates of gluconeogenesis in diabetic subjects (0.42 +/- 0.04 mmol m(-2) x min(-1), which decreased by 33% after metformin treatment (0.28 +/- 0.03 mmol x m(-2) x min(-1), P = 0.0002). There was no glycogen cycling in the control subjects, but in the diabetic subjects, glycogen cycling contributed to 25% of glucose production and explains the differences between the two methods used. In conclusion, patients with poorly controlled type 2 diabetes have increased rates of endogenous glucose production, which can be attributed to increased rates of gluconeogenesis. Metformin lowered the rate of glucose production in these patients through a reduction in gluconeogenesis.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. Basu, P. Shah, A. Basu, B. Norby, B. Dicke, V. Chandramouli, O. Cohen, B. R. Landau, and R. A. Rizza Comparison of the Effects of Pioglitazone and Metformin on Hepatic and Extra-Hepatic Insulin Action in People With Type 2 Diabetes Diabetes, January 1, 2008; 57(1): 24 - 31. [Abstract] [Full Text] [PDF]

				M. Zhou, L. Xia, and J. Wang Metformin Transport by a Newly Cloned Proton-Stimulated Organic Cation Transporter (Plasma Membrane Monoamine Transporter) Expressed in Human Intestine Drug Metab. Dispos., October 1, 2007; 35(10): 1956 - 1962. [Abstract] [Full Text] [PDF]

				A. C. Smith, K. L. Mullen, K. A. Junkin, J. Nickerson, A. Chabowski, A. Bonen, and D. J. Dyck Metformin and exercise reduce muscle FAT/CD36 and lipid accumulation and blunt the progression of high-fat diet-induced hyperglycemia Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E172 - E181. [Abstract] [Full Text] [PDF]

				P. Staehr, O. Hother-Nielsen, H. Beck-Nielsen, M. Roden, H. Stingl, J. J. Holst, P. K. Jones, V. Chandramouli, and B. R. Landau Hepatic autoregulation: response of glucose production and gluconeogenesis to increased glycogenolysis Am J Physiol Endocrinol Metab, May 1, 2007; 292(5): E1265 - E1269. [Abstract] [Full Text] [PDF]

				J. M. Lachin, C. A. Christophi, S. L. Edelstein, D. A. Ehrmann, R. F. Hamman, S. E. Kahn, W. C. Knowler, D. M. Nathan, and on behalf of the DPP Research Group Factors Associated With Diabetes Onset During Metformin Versus Placebo Therapy in the Diabetes Prevention Program Diabetes, April 1, 2007; 56(4): 1153 - 1159. [Abstract] [Full Text] [PDF]

				E. S. Jin, B.-H. Park, A. D. Sherry, and C. R. Malloy Role of Excess Glycogenolysis in Fasting Hyperglycemia Among Pre-Diabetic and Diabetic Zucker (fa/fa) Rats Diabetes, March 1, 2007; 56(3): 777 - 785. [Abstract] [Full Text] [PDF]

				V. T. Samuel, C. S. Choi, T. G. Phillips, A. J. Romanelli, J. G. Geisler, S. Bhanot, R. McKay, B. Monia, J. R. Shutter, R. A. Lindberg, et al. Targeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. Diabetes, July 1, 2006; 55(7): 2042 - 2050. [Abstract] [Full Text] [PDF]

				C. A. Collier, C. R. Bruce, A. C. Smith, G. Lopaschuk, and D. J. Dyck Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle Am J Physiol Endocrinol Metab, July 1, 2006; 291(1): E182 - E189. [Abstract] [Full Text] [PDF]

				L. Bertrand, A. Ginion, C. Beauloye, A. D. Hebert, B. Guigas, L. Hue, and J.-L. Vanoverschelde AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H239 - H250. [Abstract] [Full Text] [PDF]

				P. D. van Poelje, S. C. Potter, V. C. Chandramouli, B. R. Landau, Q. Dang, and M. D. Erion Inhibition of Fructose 1,6-Bisphosphatase Reduces Excessive Endogenous Glucose Production and Attenuates Hyperglycemia in Zucker Diabetic Fatty Rats Diabetes, June 1, 2006; 55(6): 1747 - 1754. [Abstract] [Full Text] [PDF]

				B. J. Lamont, S. Visinoni, B. C. Fam, M. Kebede, B. Weinrich, S. Papapostolou, H. Massinet, J. Proietto, J. Favaloro, and S. Andrikopoulos Expression of Human Fructose-1,6-Bisphosphatase in the Liver of Transgenic Mice Results in Increased Glycerol Gluconeogenesis Endocrinology, June 1, 2006; 147(6): 2764 - 2772. [Abstract] [Full Text] [PDF]

				S. Chevalier, S. C. Burgess, C. R. Malloy, R. Gougeon, E. B. Marliss, and J. A. Morais The Greater Contribution of Gluconeogenesis to Glucose Production in Obesity Is Related to Increased Whole-Body Protein Catabolism Diabetes, March 1, 2006; 55(3): 675 - 681. [Abstract] [Full Text] [PDF]

				D. Wang, Y. Wei, D. Schmoll, K. N. Maclean, and M. J. Pagliassotti Endoplasmic Reticulum Stress Increases Glucose-6-Phosphatase and Glucose Cycling in Liver Cells Endocrinology, January 1, 2006; 147(1): 350 - 358. [Abstract] [Full Text] [PDF]

				A. P. M. Viljanen, K. A. Virtanen, M. J. Jarvisalo, K. Hallsten, R. Parkkola, T. Ronnemaa, F. Lonnqvist, P. Iozzo, E. Ferrannini, and P. Nuutila Rosiglitazone Treatment Increases Subcutaneous Adipose Tissue Glucose Uptake in Parallel with Perfusion in Patients with Type 2 Diabetes: A Double-Blind, Randomized Study with Metformin J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6523 - 6528. [Abstract] [Full Text] [PDF]

				M. D. Erion, P. D. van Poelje, Q. Dang, S. R. Kasibhatla, S. C. Potter, M. R. Reddy, K. R. Reddy, T. Jiang, and W. N. Lipscomb MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes PNAS, May 31, 2005; 102(22): 7970 - 7975. [Abstract] [Full Text] [PDF]

				M. Foretz, N. Ancellin, F. Andreelli, Y. Saintillan, P. Grondin, A. Kahn, B. Thorens, S. Vaulont, and B. Viollet Short-Term Overexpression of a Constitutively Active Form of AMP-Activated Protein Kinase in the Liver Leads to Mild Hypoglycemia and Fatty Liver Diabetes, May 1, 2005; 54(5): 1331 - 1339. [Abstract] [Full Text] [PDF]

				H. K.R. Karlsson, K. Hallsten, M. Bjornholm, H. Tsuchida, A. V. Chibalin, K. A. Virtanen, O. J. Heinonen, F. Lonnqvist, P. Nuutila, and J. R. Zierath Effects of Metformin and Rosiglitazone Treatment on Insulin Signaling and Glucose Uptake in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Study Diabetes, May 1, 2005; 54(5): 1459 - 1467. [Abstract] [Full Text] [PDF]

				B. Kimmel and S. E. Inzucchi Oral Agents for Type 2 Diabetes: An Update Clin. Diabetes, April 1, 2005; 23(2): 64 - 76. [Abstract] [Full Text] [PDF]

				E. S. Jin, S. C. Burgess, M. E. Merritt, A. D. Sherry, and C. R. Malloy Differing mechanisms of hepatic glucose overproduction in triiodothyronine-treated rats vs. Zucker diabetic fatty rats by NMR analysis of plasma glucose Am J Physiol Endocrinol Metab, April 1, 2005; 288(4): E654 - E662. [Abstract] [Full Text] [PDF]

				M. Krssak, A. Brehm, E. Bernroider, C. Anderwald, P. Nowotny, C. D. Man, C. Cobelli, G. W. Cline, G. I. Shulman, W. Waldhausl, et al. Alterations in Postprandial Hepatic Glycogen Metabolism in Type 2 Diabetes Diabetes, December 1, 2004; 53(12): 3048 - 3056. [Abstract] [Full Text] [PDF]

				M. E. Cleasby, N. Dzamko, B. D. Hegarty, G. J. Cooney, E. W. Kraegen, and J.-M. Ye Metformin Prevents the Development of Acute Lipid-Induced Insulin Resistance in the Rat Through Altered Hepatic Signaling Mechanisms Diabetes, December 1, 2004; 53(12): 3258 - 3266. [Abstract] [Full Text] [PDF]

				C. Bouche, S. Serdy, C. R. Kahn, and A. B. Goldfine The Cellular Fate of Glucose and Its Relevance in Type 2 Diabetes Endocr. Rev., October 1, 2004; 25(5): 807 - 830. [Abstract] [Full Text] [PDF]

				M. Tiikkainen, A.-M. Hakkinen, E. Korsheninnikova, T. Nyman, S. Makimattila, and H. Yki-Jarvinen Effects of Rosiglitazone and Metformin on Liver Fat Content, Hepatic Insulin Resistance, Insulin Clearance, and Gene Expression in Adipose Tissue in Patients With Type 2 Diabetes Diabetes, August 1, 2004; 53(8): 2169 - 2176. [Abstract] [Full Text] [PDF]

				V. T. Samuel, Z.-X. Liu, X. Qu, B. D. Elder, S. Bilz, D. Befroy, A. J. Romanelli, and G. I. Shulman Mechanism of Hepatic Insulin Resistance in Non-alcoholic Fatty Liver Disease J. Biol. Chem., July 30, 2004; 279(31): 32345 - 32353. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Glycemic Treatment: Control of glycemia Diabetes Care, May 1, 2004; 27(5): 1227 - 1234. [Full Text] [PDF]

				M. D. Hein Management of Hyperglycemia in the Hospitalized Podiatric Medical Patient J Am Podiatr Med Assoc, March 1, 2004; 94(2): 135 - 148. [Abstract] [Full Text] [PDF]

				S. R. Salpeter, E. Greyber, G. A. Pasternak, and E. E. Salpeter Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis Arch Intern Med, November 24, 2003; 163(21): 2594 - 2602. [Abstract] [Full Text] [PDF]

				A. Barthel and D. Schmoll Novel concepts in insulin regulation of hepatic gluconeogenesis Am J Physiol Endocrinol Metab, October 1, 2003; 285(4): E685 - E692. [Abstract] [Full Text] [PDF]

				O. Kunert, H. Stingl, E. Rosian, M. Krssak, E. Bernroider, W. Seebacher, K. Zangger, P. Staehr, V. Chandramouli, B.R. Landau, et al. Measurement of Fractional Whole-Body Gluconeogenesis in Humans From Blood Samples Using 2H Nuclear Magnetic Resonance Spectroscopy Diabetes, October 1, 2003; 52(10): 2475 - 2482. [Abstract] [Full Text] [PDF]

				M. T. Sheehan Current Therapeutic Options in Type 2 Diabetes Mellitus: A Practical Approach Clin. Med. Res., July 1, 2003; 1(3): 189 - 200. [Abstract] [Full Text] [PDF]

				The Diabetes Prevention Program Research Group Effects of Withdrawal From Metformin on the Development of Diabetes in the Diabetes Prevention Program Diabetes Care, April 1, 2003; 26(4): 977 - 980. [Abstract] [Full Text] [PDF]

				D.-S. Wang, H. Kusuhara, Y. Kato, J. W. Jonker, A. H. Schinkel, and Y. Sugiyama Involvement of Organic Cation Transporter 1 in the Lactic Acidosis Caused by Metformin Mol. Pharmacol., April 1, 2003; 63(4): 844 - 848. [Abstract] [Full Text] [PDF]

				P. E. Carey, J. Halliday, J. E. M. Snaar, P. G. Morris, and R. Taylor Direct assessment of muscle glycogen storage after mixed meals in normal and type 2 diabetic subjects Am J Physiol Endocrinol Metab, April 1, 2003; 284(4): E688 - E694. [Abstract] [Full Text] [PDF]

				B. Schultes, K. M. Oltmanns, W. Kern, H. L. Fehm, J. Born, and A. Peters Modulation of Hunger by Plasma Glucose and Metformin J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1133 - 1141. [Abstract] [Full Text] [PDF]

				J. E. Gunton, P. J. D. Delhanty, S.-I. Takahashi, and R. C. Baxter Metformin Rapidly Increases Insulin Receptor Activation in Human Liver and Signals Preferentially through Insulin-Receptor Substrate-2 J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1323 - 1332. [Abstract] [Full Text] [PDF]

				K. A. Virtanen, K. Hallsten, R. Parkkola, T. Janatuinen, F. Lonnqvist, T. Viljanen, T. Ronnemaa, J. Knuuti, R. Huupponen, P. Lonnroth, et al. Differential Effects of Rosiglitazone and Metformin on Adipose Tissue Distribution and Glucose Uptake in Type 2 Diabetic Subjects Diabetes, February 1, 2003; 52(2): 283 - 290. [Abstract] [Full Text] [PDF]

				L. Meyer, P. Bohme, I. Delbachian, P. Lehert, N. Cugnardey, P. Drouin, and B. Guerci The Benefits of Metformin Therapy During Continuous Subcutaneous Insulin Infusion Treatment of Type 1 Diabetic Patients Diabetes Care, December 1, 2002; 25(12): 2153 - 2158. [Abstract] [Full Text] [PDF]

				K. Hallsten, K. A. Virtanen, F. Lonnqvist, H. Sipila, A. Oksanen, T. Viljanen, T. Ronnemaa, J. Viikari, J. Knuuti, and P. Nuutila Rosiglitazone but Not Metformin Enhances Insulin- and Exercise-Stimulated Skeletal Muscle Glucose Uptake in Patients With Newly Diagnosed Type 2 Diabetes Diabetes, December 1, 2002; 51(12): 3479 - 3485. [Abstract] [Full Text] [PDF]

				S. K. Tigas, A. L. Sunehag, and M. W. Haymond Impact of Duration of Infusion and Choice of Isotope Label on Isotope Recycling in Glucose Homeostasis Diabetes, November 1, 2002; 51(11): 3170 - 3175. [Abstract] [Full Text] [PDF]

				H. Stingl, W. J. Schnedl, M. Krssak, E. Bernroider, M. G. Bischof, T. Lahousen, G. Pacini, and M. Roden Reduction of Hepatic Glycogen Synthesis and Breakdown in Patients with Agenesis of the Dorsal Pancreas J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4678 - 4685. [Abstract] [Full Text] [PDF]

				D.-S. Wang, J. W. Jonker, Y. Kato, H. Kusuhara, A. H. Schinkel, and Y. Sugiyama Involvement of Organic Cation Transporter 1 in Hepatic and Intestinal Distribution of Metformin J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 510 - 515. [Abstract] [Full Text] [PDF]

				D. Dietze, M. Koenen, K. Rohrig, H. Horikoshi, H. Hauner, and J. Eckel Impairment of Insulin Signaling in Human Skeletal Muscle Cells by Co-Culture With Human Adipocytes Diabetes, August 1, 2002; 51(8): 2369 - 2376. [Abstract] [Full Text] [PDF]

				L. G. D. Fryer, A. Parbu-Patel, and D. Carling The Anti-diabetic Drugs Rosiglitazone and Metformin Stimulate AMP-activated Protein Kinase through Distinct Signaling Pathways J. Biol. Chem., July 5, 2002; 277(28): 25226 - 25232. [Abstract] [Full Text] [PDF]

				D. Kirpichnikov, S. I. McFarlane, and J. R. Sowers Metformin: An Update Ann Intern Med, July 2, 2002; 137(1): 25 - 33. [Abstract] [Full Text] [PDF]

				N. Musi, M. F. Hirshman, J. Nygren, M. Svanfeldt, P. Bavenholm, O. Rooyackers, G. Zhou, J. M. Williamson, O. Ljunqvist, S. Efendic, et al. Metformin Increases AMP-Activated Protein Kinase Activity in Skeletal Muscle of Subjects With Type 2 Diabetes Diabetes, July 1, 2002; 51(7): 2074 - 2081. [Abstract] [Full Text] [PDF]

				S. E. Inzucchi Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review JAMA, January 16, 2002; 287(3): 360 - 372. [Abstract] [Full Text] [PDF]

				T. P. Ciaraldi, A. P.S. Kong, N. V. Chu, D. D. Kim, S. Baxi, M. Loviscach, R. Plodkowski, R. Reitz, M. Caulfield, S. Mudaliar, et al. Regulation of Glucose Transport and Insulin Signaling by Troglitazone or Metformin in Adipose Tissue of Type 2 Diabetic Subjects Diabetes, January 1, 2002; 51(1): 30 - 36. [Abstract] [Full Text] [PDF]

				B. R. Landau Methods for measuring glycogen cycling Am J Physiol Endocrinol Metab, September 1, 2001; 281(3): E413 - E419. [Abstract] [Full Text] [PDF]

				S. Song, S. Andrikopoulos, C. Filippis, A. W. Thorburn, D. Khan, and J. Proietto Mechanism of fat-induced hepatic gluconeogenesis: effect of metformin Am J Physiol Endocrinol Metab, August 1, 2001; 281(2): E275 - E282. [Abstract] [Full Text] [PDF]